Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study

The C-Word: Scientific Euphemisms Do Not Improve Causal Inference From Observational Data

(2018) Miguel A. Hernán   AMERICAN JOURNAL OF PUBLIC HEALTH

Life expectancy difference and life expectancy ratio: two measures of treatment effects in randomised trials with non-proportional hazards

(2017) Hakim-Moulay Dehbi et al.   BMJ-British Medical Journal

Life expectancy difference and life expectancy ratio: two measures of treatment effects in randomised trials with non-proportional hazards

(2017) Hakim-Moulay Dehbi et al.   BMJ-British Medical Journal

Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available: Table 1.

(2016) Miguel A. Hernán et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY

Comparative efficacy of tocilizumab, abatacept and rituximab after non-TNF inhibitor failure: results from a multicentre study

(2016) Tristan Pascart et al.   International Journal of Rheumatic Diseases

Brief Report: Association of Rheumatoid Factor and Anti-Citrullinated Protein Antibody Positivity With Better Effectiveness of Abatacept: Results From the Pan-European Registry Analysis

(2016) J. E. Gottenberg et al.   Arthritis & Rheumatology

Rituximab done: what’s next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritis

(2015) Ulrich A. Walker et al.   RHEUMATOLOGY

Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies

(2015) Peter C. Austin et al.   STATISTICS IN MEDICINE

Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy

(2014) Sudipto Das et al.   ANNALS OF THE RHEUMATIC DISEASES

Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial

(2013) Michael Schiff et al.   ANNALS OF THE RHEUMATIC DISEASES

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial

(2013) Cem Gabay et al.   LANCET

Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the ‘Orencia and Rheumatoid Arthritis’ registry

(2012) J E Gottenberg et al.   ANNALS OF THE RHEUMATIC DISEASES

Comparative effectiveness and safety of biological treatment options after tumour necrosis factor α inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis

(2012) Monika Schoels et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry

(2011) H. C. Leffers et al.   ANNALS OF THE RHEUMATIC DISEASES

The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt

(2011) Patrick Royston et al.   STATISTICS IN MEDICINE

Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis

(2010) C. Salliot et al.   ANNALS OF THE RHEUMATIC DISEASES

Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry

(2010) J.-E. Gottenberg et al.   ARTHRITIS AND RHEUMATISM

Rheumatoid arthritis

(2010) David L Scott et al.   LANCET

Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries

(2010) X. Mariette et al.   RHEUMATOLOGY

Indirect Comparison of Tocilizumab and Other Biologic Agents in Patients with Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs

(2010) Gert J.D. Bergman et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry

(2009) Merete Lund Hetland et al.   ARTHRITIS AND RHEUMATISM

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

(2008) P. Emery et al.   ANNALS OF THE RHEUMATIC DISEASES